25 results  1 of 2 

1 Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice
Juyoung Shin, Raeun Kim, Hun-Sung Kim
Cardiovasc Prev Pharmacother.2023;5(2):49-53.   Published online 2023 April 28     DOI: http://dx.doi.org/10.36011/cpp.2023.5.e7
      
2 Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Tzu-Yi Lin, Eugene Yu-Chuan Kang, Shih-Chieh Shao, Edward Chia-Cheng Lai, Sunir J. Garg, Kuan-Jen Chen, Je-Ho Kang, Wei-Chi Wu, Chi-Chun Lai, Yih-Shiou Hwang
Diabetes Metab J.2023;47(3):394-404.   Published online 2023 March 6     DOI: http://dx.doi.org/10.4093/dmj.2022.0221
      
3 The effects and side effects of liraglutide as a treatment for obesity
Jeonghoon Ha, Jin Yu, Joonyub Lee, Hun-Sung Kim
Cardiovasc Prev Pharmacother.2022;4(4):142-148.   Published online 2022 October 20     DOI: http://dx.doi.org/10.36011/cpp.2022.4.e18
      
4 Effect of the Glucagon-Like Peptide-1 Receptor Agonists on Autonomic Function in Subjects with Diabetes: A Systematic Review and Meta-Analysis
Carla Greco, Daniele Santi, Giulia Brigante, Chiara Pacchioni, Manuela Simoni
Diabetes Metab J.2022;46(6):901-911.   Published online 2022 April 12     DOI: http://dx.doi.org/10.4093/dmj.2021.0314
      
5 Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway
Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
Endocrinol Metab.2022;37(1):74-83.   Published online 2022 February 9     DOI: http://dx.doi.org/10.3803/EnM.2021.1293
   
6 Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study
Hwi Seung Kim, Taekwan Yoon, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee
Diabetes Metab J.2022;46(4):658-662.   Published online 2021 November 8     DOI: http://dx.doi.org/10.4093/dmj.2021.0232
      
7 Cardiorenal Protection in Diabetic Kidney Disease
Jason F. Lee, Ecaterina Berzan, Vikas S. Sridhar, Ayodele Odutayo, David Z.I. Cherney
Endocrinol Metab.2021;36(2):256-269.   Published online 2021 April 19     DOI: http://dx.doi.org/10.3803/EnM.2021.987
      
8 Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020
Eun-Jung Rhee, Mee-Kyung Kim, Won-Young Lee
Endocrinol Metab.2021;36(1):41-50.   Published online 2021 February 24     DOI: http://dx.doi.org/10.3803/EnM.2021.106
      
9 Paradigm Shift for the Treatment of Type 2 Diabetes Mellitus in Patients with Cardiovascular Disease: Cardiologist's Perspective
Doo Soo Jeon
Cardiovasc Prev Pharmacother.2020;2(1):11-17.   Published online 2020 January 31     DOI: http://dx.doi.org/10.36011/cpp.2020.2.e4
      
10 Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist
Inkuk Lee, Eun Seok Kang
J Korean Diabetes.2019;20(3):149-156.   Published online 2019 September 30     DOI: http://dx.doi.org/10.4093/jkd.2019.20.3.149
      
11 A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Jack Alistair Sargeant, Joseph Henson, James Adam King, Thomas Yates, Kamlesh Khunti, Melanie Jane Davies
Endocrinol Metab.2019;34(3):247-262.   Published online 2019 September 26     DOI: http://dx.doi.org/10.3803/EnM.2019.34.3.247
   
12 Effect of Nutrient Preload and Food Order on Glucose, Insulin, and Gut Hormones
Jae Hyun Bae, Young Min Cho
J Korean Diabetes.2018;19(4):193-199.   Published online 2018 December 28     DOI: http://dx.doi.org/10.4093/jkd.2018.19.4.193
      
13 Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet
Vincenza Spallone
Diabetes Metab J.2019;43(1):3-30.   Published online 2018 November 2     DOI: http://dx.doi.org/10.4093/dmj.2018.0259
      
14 Paradigm Changes in Diabetes Management Guidelines: American Diabetes Association 2018
Jeong Hyun Park
J Korean Diabetes.2018;19(2):71-75.   Published online 2018 June 30     DOI: http://dx.doi.org/10.4093/jkd.2018.19.2.71
      
15 Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist)
In-Kyung Jeong
J Lipid Atheroscler.2018;7(1):32-41.   Published online 2018 June 27     DOI: http://dx.doi.org/10.12997/jla.2018.7.1.32
      
16 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
Hyun Jin Kim
J Korean Diabetes.2018;19(1):35-40.   Published online 2018 March 27     DOI: http://dx.doi.org/10.4093/jkd.2018.19.1.35
      
17 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
Hyun Jin Kim, Seok O Park, Seung-Hyun Ko, Sang Youl Rhee, Kyu-Yeon Hur, Nan-Hee Kim, Min Kyong Moon, Byung-Wan Lee, Jin Hwa Kim, Kyung Mook Choi,
Diabetes Metab J.2017;41(6):423-429.   Published online 2017 December 19     DOI: http://dx.doi.org/10.4093/dmj.2017.41.6.423
      
18 New anti-diabetic agents
Doo-Man Kim
J Korean Med Assoc.2017;60(12):992-997.   Published online 2017 December 14     DOI: http://dx.doi.org/10.5124/jkma.2017.60.12.992
      
19 New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes
Won-Young Lee
Endocrinol Metab.2017;32(1):1-5.   Published online 2017 February 6     DOI: http://dx.doi.org/10.3803/EnM.2017.32.1.1
   
20 An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
Suk Chon, Jean-François Gautier
Diabetes Metab J.2016;40(2):99-114.   Published online 2016 April 25     DOI: http://dx.doi.org/10.4093/dmj.2016.40.2.99
      

 1 of 2